United States securities and exchange commission logo





                       September 21, 2021

       Yulin Wang
       Chief Executive Officer
       Meihua International Medical Technologies Co., Ltd.
       88 Tongda Road, Touqiao Town
       Guangling District, Yangzhou, 225000
       People   s Republic of China

                                                        Re: Meihua
International Medical Technologies Co., Ltd.
                                                            Amendment No. 2 to
                                                            Registration
Statement on Form F-1
                                                            Filed September 13,
2021
                                                            File No. 333-258659

       Dear Mr. Wang:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
 Yulin Wang
FirstName LastNameYulin    Wang
Meihua International Medical Technologies Co., Ltd.
Comapany 21,
September NameMeihua
              2021      International Medical Technologies Co., Ltd.
September
Page 2    21, 2021 Page 2
FirstName LastName
Amendment No. 2 to Form F-1 filed September 13, 2021

Prospectus Summary, page 1

1.       We note that China-based subsidiaries constitute a material part of
your consolidated
         financial statements. Please provide in tabular form condensed
consolidating schedule
         depicting the financial position, cash flows and results of operations
for the parent, its
         China-based subsidiaries, and any eliminating adjustments separately -
as of the same
         dates and for the same periods for which audited consolidated
financial statements are
         required. Highlight the financial statement information related to the
China-based
         subsidiaries and parent, so an investor may evaluate the nature of
assets held by, and the
         operations of, entities apart from the China-based subsidiaries, which
includes the cash
         held and transferred among entities.
       You may contact Tracey Houser at 202-551-3736 or Brian Cascio at
202-551-3676 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Celeste Murphy at 202-551-3257 with any
other questions.



                                                               Sincerely,

                                                               Division of
Corporation Finance
                                                               Office of Life
Sciences
cc:      Joe Laxague, Esq.